|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM063566893 |
| 003 |
DE-627 |
| 005 |
20231221223946.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0212.xml
|
| 035 |
|
|
|a (DE-627)NLM063566893
|
| 035 |
|
|
|a (NLM)6379679
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Janke, P G
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritic patients
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.09.1984
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Ninety-five geriatric patients with osteoarthritis of the hip and/or knee were entered into an open parallel group study of sulindac (400 mg/day) and naproxen (500 mg/day), both given in twice-daily regimens. Patients received the drugs for 12 weeks. Both drugs produced improvements in the patients' overall condition. There were no statistically significant differences between the effects of the two drugs. Overall, both drugs proved beneficial and well tolerated
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Indenes
|2 NLM
|
| 650 |
|
7 |
|a Sulindac
|2 NLM
|
| 650 |
|
7 |
|a 184SNS8VUH
|2 NLM
|
| 650 |
|
7 |
|a Naproxen
|2 NLM
|
| 650 |
|
7 |
|a 57Y76R9ATQ
|2 NLM
|
| 700 |
1 |
|
|a Diggins, J B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Currie, W J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dasgupta, P K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Glick, E N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sheikh, N A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shujja-Ud-Din
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 10 vom: 20., Seite 663-7
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:10
|g day:20
|g pages:663-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 1984
|e 10
|b 20
|h 663-7
|